DRREDDY1,141.00

Dr. Reddy's Laboratories Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersSUNPHARMACIPLALUPINAPOLLOHOSPMAXHEALTHDIVISLABTORNTPHARMZYDUSLIFEMcap ₹95,274 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q2 FY24
30/09/2023
Q3 FY24
31/12/2023
Q4 FY24
31/03/2024
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations6,902.67,236.87,113.87,696.18,038.28,381.28,528.48,572.18,828.38,753.47,546.48,099.8
Other Income315.0216.2197.5187.2307.5150.2522.1290.3323.9268.8475.4354.7
Total Income7,217.67,453.07,311.37,883.38,345.78,531.49,050.58,862.49,152.29,022.28,021.88,454.5
Expenses
+ Cost of Materials Consumed955.91,141.21,096.21,227.21,287.21,452.61,716.52,035.81,441.31,825.51,198.61,653.8
+ Purchases of Stock-in-Trade1,137.81,208.31,175.91,380.11,282.81,050.71,127.51,215.91,745.91,542.11,657.71,973.8
+ Changes in Inventories-90.7-173.5-180.0-425.6-203.378.26.0-444.2-63.5-272.3356.4-242.5
+ Employee Benefit Expense1,280.31,276.41,283.61,413.71,399.21,366.51,400.61,503.51,452.11,588.51,446.81,651.6
+ Finance Costs35.339.459.359.875.781.765.683.090.794.4105.7125.5
+ Depreciation & Amortisation375.5373.5367.7380.6397.0471.4454.7476.1504.6521.0557.1536.6
+ Other Expenses1,611.01,761.31,906.91,970.82,195.82,160.22,279.92,087.52,242.62,182.12,504.42,203.2
Total Expenses5,305.15,626.65,709.66,006.66,434.46,661.37,050.86,957.67,413.77,481.37,826.77,902.0
EBITDA2,008.32,023.11,831.22,129.92,076.52,273.01,997.92,173.62,009.91,887.5382.5859.9
EBIT1,632.81,649.61,463.51,749.31,679.51,801.61,543.21,697.51,505.31,366.5-174.6323.3
Profit
PBT before Exceptional Items1,912.51,826.41,601.71,876.71,911.31,870.11,999.71,904.81,738.51,540.9195.1552.5
Pretax Income1,912.51,826.41,601.71,876.71,911.31,870.11,999.71,904.81,738.51,540.9195.1552.5
+ Current Tax590.1353.8282.3521.5771.3533.0432.31,026.1184.7207.4-23.7157.5
+ Deferred Tax-155.694.413.1-31.3-195.8-62.9-13.8-531.0223.3146.22.1-39.8
Tax Expense434.5448.2295.4490.2575.5470.1418.5495.1408.0353.6-21.6117.7
+ Share of Associates & JVs4.22.73.55.96.14.25.50.26.32.34.60.8
Net Income1,482.21,380.91,309.81,392.41,341.91,404.21,586.71,409.91,336.81,189.6221.3435.6
+ Net Income — Continuing Ops1,478.01,378.21,306.31,386.51,335.81,400.01,581.21,409.71,330.51,187.3216.7434.8
+ Other Comprehensive Income-113.499.2-55.71.8296.1-202.4109.4204.9111.8177.0245.8155.0
Total Comprehensive Income1,368.81,480.11,254.11,394.21,638.01,201.81,696.11,614.81,448.61,366.6467.1590.6
Net Income to Common0.00.00.01,255.71,413.71,593.31,418.11,347.11,209.9220.9444.3
Minority Interest0.00.00.086.2-9.5-6.6-8.2-10.3-20.30.4-8.7
Per Share
Basic EPS89.0982.9478.6683.6115.0816.9719.1217.0416.1814.532.655.33
Diluted EPS88.9182.8178.5383.4815.0516.9419.1017.0216.1714.522.655.33
Other Comprehensive Income — detail
+ Other Comprehensive Income109.4204.9111.8177.0245.8155.0
+ Items NOT to be Reclassified to P&L-22.213.2-4.4-9.1-3.3-5.2-11.70.5-1.4-1.616.8-0.7
+ Tax on Items NOT to be Reclassified-2.40.00.00.05.6-0.2
+ Tax on Items NOT to be Reclassified — alt tag0.00.0-0.40.00.00.0
+ Items to be Reclassified to P&L-111.378.2-56.511.5297.8-214.2142.5207.786.2181.0216.7188.8
+ Tax on Items to be Reclassified23.83.3-27.02.4-17.933.3
+ Tax on Items to be Reclassified — alt tag-20.1-7.8-4.80.6-1.6-17.0
Comprehensive Income — Owners of Parent1,368.81,480.11,254.11,394.21,551.81,211.31,702.71,623.01,458.91,386.9466.7599.3
Comprehensive Income — Non-controlling Interests0.00.00.00.086.2-9.5-6.6-8.2-10.3-20.30.4-8.7
Per Share — as-filed variants
Basic EPS — Continuing Operations89.0982.9478.6683.6115.0816.9719.1217.0416.1814.532.655.33
Diluted EPS — Continuing Operations88.9182.8178.5383.4815.0516.9419.1017.0216.1714.522.655.33
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit4,899.65,060.85,021.75,514.45,671.55,799.75,678.45,764.65,704.65,658.14,333.74,714.7
Gross Margin %70.9869.9370.5971.6570.5669.2066.5867.2564.6264.6457.4358.21
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)1,912.51,826.41,601.71,876.71,911.31,870.11,999.71,904.81,738.51,540.9195.1552.5
Net Income Adj (tax-effected)1,482.21,380.91,309.81,392.41,341.91,404.21,586.71,409.91,336.81,189.6221.3435.6
EPS Adj89.0982.9478.6683.6115.0816.9719.1217.0416.1814.532.655.33
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value5.005.000.005.001.001.001.001.001.001.001.001.00
Paid Up Equity Capital83.483.483.483.483.483.483.483.583.583.583.583.5
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.